COSENTYX (Secukinumab)

Skinmed. 2015 Aug 1;13(4):303-6. eCollection 2015 Jul-Aug.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Clinical Trials, Phase III as Topic
  • Drug Approval
  • Humans
  • Interleukin-17 / antagonists & inhibitors*
  • Psoriasis / drug therapy*
  • Psoriasis / pathology
  • United States
  • United States Food and Drug Administration

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Interleukin-17
  • secukinumab